Revolution Medicines Stock Surges 132% on Daraxonrasib Trial Data
Revolution Medicines (RVMD) shares up 132% YTD. Daraxonrasib beat chemo in pancreatic cancer (13.2 vs 6.7 months median OS). Company has no marketed products and a $39B valuation.
News & Analysis
Curated news and analysis on clinical trials, drug approvals, and medical research.
AI Drug Discovery Surges With $2.5B Partnership and $1.7B Takeda-Iambic Deal
AI drug discovery is moving from hype to proof in 2026, with multi-billion-dollar partnerships, new joint initiatives, and major investments accelerating AI-native biotech pipelines and data-driven deals.
Medidata Launches Medidata Plus, AI-Native Platform to Scale Clinical Trial Portfolios
Medidata launched Medidata Plus, an AI-native foundation that unifies AI capabilities across the clinical trial lifecycle. The platform accelerates study builds, enables no-code data transformation, and supports 80% of FDA novel drug approvals in 2025.
NIH Expands All of Us Dataset with 747,000 Participants' Genomics and Health Data
NIH expanded its All of Us dataset, linking 535,000 whole genome sequences to 482,000 EHRs from 747,000 participants. The release includes 1.3 billion variants and aims to advance precision medicine, prioritizing underrepresented populations.
AstraZeneca Reports Strong Q1 2026 Results; Stock Sees Unusual Options Activity
AstraZeneca reported strong Q1 2026 results with 8% revenue growth and 12% operating profit growth, driven by its oncology portfolio and pipeline progress. The company also saw unusual options activity and maintained full-year guidance. Key oncology brands including Imfinzi and Enhertu showed double-digit growth.
FDA Approves Leqembi Subcutaneous Starting Dose; Real-World Data and KCL-286 Show Progress
FDA approved a subcutaneous starting dose of Leqembi for early Alzheimer's disease. AAIC 2026 real-world data showed most patients stable or improved; a mouse study found KCL-286 repaired DNA damage and reduced inflammation.
First Patient Dosed in Phase 1 Trial of Off-the-Shelf TCR-NK Therapy ZI-MA4-1 for Solid Tumors
Dosing has begun in a Phase 1 trial of ZI-MA4-1, the first MAGE-A4-targeting TCR-NK cell therapy for solid tumours, with initial data expected from mid-2026. The off-the-shelf therapy is being evaluated at two UK sites.
Trump's Gaza Board of Peace Holds Inaugural Meeting as Director-General Visits Israel
Trump's Gaza Board of Peace holds its first meeting as Director-General Mladenov visits Israel to discuss Phase II of the ceasefire, amid IDF strikes. Indonesia plans to send troops, and dozens of countries have joined, pledging over $5 billion.
High Biomarker Testing Rates Achieved Across Racial Groups in Metastatic Triple-Negative Breast Cancer, Yet Disparities Persist
A study of 450 mTNBC patients in community practices found high biomarker testing rates and encouraging outcomes across racial groups, with Hispanic patients showing the longest survival. However, Black women of West African ancestry face the highest TNBC incidence and greater neuropathy from paclitaxel, making docetaxel a potential alternative. Social determinants like neighborhood deprivation and allostatic load are also linked to TNBC risk.
340B Drug Pricing Program Under Fire: Fraud, Profits, and Reform Proposals
The 340B Drug Pricing Program faces scrutiny after a Florida fraud case and data showing hospitals earn billions in profits. Lawmakers propose new accountability measures, while hospital advocates defend its role in funding community care.
Tuberculous Meningitis Remains Most Common CNS Infection in Philippine Adults
A retrospective study of 184 adults with central nervous system infections in the Philippines found tuberculous meningitis as the leading cause. Common symptoms included fever, headache, and neurologic deficits; CSF culture yield was just 25%. Findings call for updated local guidelines amid rising antimicrobial resistance.
Global CNS Therapeutics Market to Reach $285.72 Bn by 2035, Growing at 8.64% CAGR
The global CNS therapeutics market was valued at USD 127.29 billion in 2025 and is projected to reach USD 285.72 billion by 2035, driven by demand for Alzheimer’s and Parkinson’s treatments. North America held 45% of the market; neurodegenerative diseases were the largest segment. Private investment and trends toward biologics and AI are shaping the sector.
Moderna Reports Q2 2026 Loss, Trims 2026 Spending, Advances mFLUSIVA PDUFA
Moderna posted Q2 2026 revenue of $145 million and a GAAP net loss of $0.8 billion, while improving its 2026 spending outlook. Its norovirus candidate missed Phase 3 interim criteria, and mFLUSIVA faces an August 5 PDUFA decision.
Grail's Galleri Blood Test Fails to Reduce Late-Stage Cancers in Major Trial
A major clinical trial found that Grail's Galleri blood test did not reduce late-stage cancer diagnoses, raising questions about multi-cancer early detection. Meanwhile, the FDA approved a second blood-based colorectal cancer screening test, and an AI-powered liquid biopsy showed promise for Ewing sarcoma.
Moderna Reports Q2 and Q1 Losses, Appoints New Chief Commercial Officer
Moderna reported a second-quarter loss of $782 million and a first-quarter loss of $1.34 billion, both beating expectations. The company appointed a new Chief Commercial Officer ahead of vaccine launches and disclosed CFO restricted stock unit transactions.
South Korean Police Apprehend 5,200 Drug Offenders in Crackdown as Doctor Arrests Hit Record 395
South Korean police arrested 5,203 drug offenders in a four-month crackdown, with distribution arrests up 39.2%. Doctor arrests hit a record 395 last year, fueled by high-profile propofol cases. Authorities are expanding undercover operations and social media monitoring.
GLP-1 Access Gaps: Compounded Market Robust, Pediatric Prescribing Limited
Despite end of GLP-1 shortages, compounded products remain widely available, some from pharmacies with regulatory issues. Only 20% of eligible children at a CHOP clinic got prescriptions, and 60% faced interruptions, often from cost.
U.S. and Global Funders Announce New Life Sciences and Biotech Opportunities
Federal and international funders have announced life sciences and biotech funding opportunities: NIH awards up to $30 million, NSF fellowships, and roundups exceeding $900 million. Scholarships and grants are open worldwide, with AI and local eligibility as key criteria.
FABP2 Suppresses Colon Cancer Liver Metastasis by Promoting Ferroptosis Sensitivity
A study finds that FABP2 suppresses colon cancer liver metastasis by increasing ferroptosis sensitivity via β-catenin/GPX4 pathway regulation. Low FABP2 expression correlates with poor survival in advanced colon cancer.
Medivir Raises Capital for MIV-711 LCPD Indication, OI Trial Advances
Medivir AB completed an oversubscribed share issue to fund MIV-711 for Legg-Calvé-Perthes disease. MIV-711 is advancing to phase II for osteogenesis imperfecta with FDA orphan drug status. Cash runway extends to 2028 and other pipeline programs are progressing.
Showing 20 articles per page